Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 15 tags : Trial save search
Canoo Selects Northwest Arkansas for its Headquarters, R&D Center and EV Industrialization Facility
Published: 2021-11-15 (Crawled : 00:00) - prnewswire.com
GOEV 4 | $2.89 -8.83% -6.38% 3.9M
|
|
| O: 0.12%
H: 22.96%
C: 21.79%
trial
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
Published: 2021-11-15 (Crawled : 18:00) - metacrine.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 1.6%
H: 2.36%
C: -0.79%
diabetes phase 2 results topline nash trial phase 2b
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
Published: 2021-11-15 (Crawled : 17:00) - biospace.com/
PHAS | $0.0701 -23.97%
|
Health Technology
|
| O: 1.35%
H: 8.8%
C: -19.47%
bleeding results phase 3 trial bentracimab
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
Published: 2021-11-15 (Crawled : 15:30) - biospace.com/
MIST | $1.67 -1.77% -1.8% 43K
|
Health Technology
|
| O: 9.59%
H: 13.29%
C: 12.64%
presentation heart trial milestone
Modine Names Mario Signorini as General Manager, Global Refrigeration & Industrial Coolers
Published: 2021-11-15 (Crawled : 15:00) - prnewswire.com
MOD | $90.99 2.18% 0.0% 1.2M
|
Producer Manufacturing
|
| O: 0.53%
H: 0.96%
C: 0.35%
IEX | $224.64 -3.28% 0.0% 580K
|
Producer Manufacturing
|
| O: 0.29%
H: 0.27%
C: -0.48%
trial
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
BHVN | News 0 d | $38.72 -2.25% -0.28% 970K
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: -4.17%
platform trial als enroll
PINC AI™ Applied Sciences (PAS) and Mölnlycke Health Care AB Clinical Trial Aims to Reduce Hospital-Acquired Infections (HAIs)
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
PINC | $21.125 0.45% 0.45% 1.2M
|
Health Services
|
| O: 0.28%
H: 1.84%
C: -1.59%
acquired trial injection infections
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency- Preliminary biomarker and safety data expected in the first half of 2022 -
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
INZY | $4.4 0.0% 480K
|
Health Technology
|
| O: 0.6%
H: 1.39%
C: -0.5%
trial biomarkers
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
IMMP | $2.59 3.19% 3.09% 1.4M
|
Health Technology
|
| O: 0.47%
H: 1.16%
C: -0.93%
positive therapy trial
Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial
Published: 2021-11-15 (Crawled : 13:30) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K
|
|
| O: -3.4%
H: 18.16%
C: 17.77%
platform trial als enroll
Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting
Published: 2021-11-15 (Crawled : 13:30) - globenewswire.com
ONCT | $8.755 -0.11% -0.11% 1.6K
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
ewing sarcoma phase 1 trial
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
Published: 2021-11-15 (Crawled : 13:30) - biospace.com/
CELC | $16.9 -1.97% -2.01% 90K
|
Commercial Services
|
| O: -4.0%
H: 1.15%
C: 1.15%
collaboration phase 3 trial
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: -23.94%
disease phase 1 positive trial phase 2 phase 3 rp-a501 danon disease
GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
GLYC | $1.855 1.09% 1.08% 660K
|
Health Technology
|
| O: 0.47%
H: 2.8%
C: 0.0%
myeloid leukemia leukemia phase 3 trial enroll acute myeloid leukemia aml
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
NVCR | $12.35 2.45% 2.39% 1.1M
|
Health Technology
|
| O: 3.0%
H: 0.39%
C: -3.17%
phase 2 positive results trial topline glioblastoma
Industrial Energy Efficiency Services Market Research Report Highlights the Key Findings in the Area of Vendor Landscape, Key Market Segments, Regions, and Latest Trends and Drivers | Technavio
Published: 2021-11-15 (Crawled : 10:00) - prnewswire.com
JCI | News S | $64.61 -0.86% 0.0% 7.3M
|
Producer Manufacturing
|
| O: 1.65%
H: 0.0%
C: 0.0%
HON | News M | $194.72 -0.73% -0.74% 3.4M
|
Producer Manufacturing
|
| O: 0.35%
H: 0.0%
C: 0.0%
energy test research trial
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
Published: 2021-11-15 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.9%
H: 0.08%
C: -0.37%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 1.35%
H: 0.0%
C: -1.12%
results trial macular
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
Published: 2021-11-15 (Crawled : 01:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 7.99%
H: 0.0%
C: 0.0%
presentation heart phase 3 trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.